Genome machine learning company Deep Genomics is using artificial intelligence to develop drugs to tackle diseases related to gene defects . The company analyses genomic data using algorithms to identify the genes intrinsic to particular illnesses , making it an ideal for developing highly - targeted drugs . Deep Gen will first focus on early stage drug development for Mendelian disorders , which are caused by a specific genetic mutation which affects around 350 million people globally .
Genome machine learning company Deep Genomics is using artificial intelligence to develop drugs to tackle diseases related to gene defects. The company analyses genomic data using algorithms to identify the genes intrinsic to particular illnesses, making it an ideal for developing highly-targeted drugs. Deep Genomics will first focus on early stage drug development for Mendelian disorders, which are caused by one specific genetic mutation which affects around 350 million people globally.